Operationalizing Screening for Non-Small Cell Lung Cancer: An International Discussion

This series highlights an international exchange between a US oncologist and a German oncologist on screening and testing practices for non-small cell lung cancer (NSCLC). Experts discuss the current landscape of testing panels and share practical pearls on improving efficiencies in daily practice.

EP. 1: Global Perspectives on Lung Cancer: Targeted Therapy and Better Outcomes

November 24th 2025

Experts discuss the transformative impact of targeted therapies on outcomes in non-small cell lung cancer (NSCLC). They highlight that before these treatments, survival for stage IV patients was often measured in months. Now, the identification of driver mutations and the use of matched oral targeted therapies have fundamentally changed the disease trajectory.

EP. 2: Implementing Comprehensive Genomic Testing in NSCLC Care

November 24th 2025

Experts address the critical practice of comprehensive biomarker testing for non-small cell lung cancer (NSCLC), highlighting both its necessity and the challenges in implementation. While biomarker testing is mandatory from diagnosis per guidelines, real-world barriers like insufficient tissue from biopsies often prevent complete profiling.

EP. 3: Why Fast Biomarker Results are Critical for NSCLC Patients

December 1st 2025

Experts discuss the critical importance of turnaround time for comprehensive biomarker testing in NSCLC. They compare systems, with one center performing in-house NGS testing and reporting key results like EGFR and ALK via rapid FISH/PCR in 3-5 days, allowing for immediate treatment decisions without waiting for the full NGS report.

EP. 4: International Dialogue on Which Biomarkers to Prioritize in NSCLC Testing

December 1st 2025

Experts underscore that comprehensive biomarker testing is now essential not just for stage IV non-small cell lung cancer (NSCLC), but also for earlier stages, starting from stage 1b. This is driven by the approval of adjuvant targeted therapies and neoadjuvant regimens, making molecular profiling critical for curative-intent treatment planning.